Montreal-based biopharmaceutical firm Milestone Pharmaceuticals Inc. has dedicated its efforts to the development and commercialization of cardiovascular medicines. The company's leading product candidate, etripamil - hailed as a potent and novel calcium channel blocker - has entered the Phase III clinical trial stage for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, and is also in Phase II clinical trials for the treatment of atrial fibrillation and rapid ventricular rate. With a license and collaboration agreement in place with Ji Xing Pharmaceuticals, Milestone Pharmaceuticals' human prophylactic and therapeutic uses of etripamil are also set to be developed and commercialized. Milestone Pharmaceuticals Inc. was founded in 2003.
Milestone Pharmaceuticals Inc.'s ticker is MIST
The company's shares trade on the LSE stock exchange
They are based in Montreal, Quebec
There are 11-50 employees working at Milestone Pharmaceuticals Inc.
It is https://www.milestonepharma.com/
Milestone Pharmaceuticals Inc. is in the Healthcare sector
Milestone Pharmaceuticals Inc. is in the Biotechnology industry
The following five companies are Milestone Pharmaceuticals Inc.'s industry peers:
- Adverum Biotechnologies, Inc.